Lyme Disease - Pipeline Review, H2 2019
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Lyme Disease - Pipeline Review, H2 2019
Summary
Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Lyme Disease - Pipeline Review, H2 2019, provides an overview of the Lyme Disease (Infectious Disease) pipeline landscape.
Lyme disease is a bacterial infection transmitted by a tick. Lyme disease is caused by the bacterium Borrelia burgdorferi. Symptoms include rash, fever, chills, fatigue, body aches and headache. Risk factors include age, gender and geographic locations. Treatment includes antibiotics.
Report Highlights
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Lyme Disease - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Lyme Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Lyme Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Lyme Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Lyme Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Lyme Disease (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Lyme Disease (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Lyme Disease (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Lyme Disease (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Lyme Disease (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Lyme Disease (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Lyme Disease (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Summary
Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Lyme Disease - Pipeline Review, H2 2019, provides an overview of the Lyme Disease (Infectious Disease) pipeline landscape.
Lyme disease is a bacterial infection transmitted by a tick. Lyme disease is caused by the bacterium Borrelia burgdorferi. Symptoms include rash, fever, chills, fatigue, body aches and headache. Risk factors include age, gender and geographic locations. Treatment includes antibiotics.
Report Highlights
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Lyme Disease - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Lyme Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Lyme Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Lyme Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Lyme Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Lyme Disease (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Lyme Disease (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Lyme Disease (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Lyme Disease (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Lyme Disease (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Lyme Disease (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Lyme Disease (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
TABLE OF CONTENTS
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Lyme Disease - Overview
Lyme Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Lyme Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Lyme Disease - Companies Involved in Therapeutics Development
Inovio Pharmaceuticals Inc
NovoBiotic Pharmaceuticals LLC
Valneva SE
Lyme Disease - Drug Profiles
azithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Inhibit CRASP1 for Lyme Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
desloratadine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit OspA for Lyme Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lyme disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lyme disease vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Outer Surface Protein A for Lyme Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Lyme Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Lyme Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VLA-15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lyme Disease - Dormant Projects
Lyme Disease - Product Development Milestones
Featured News & Press Releases
Jul 03, 2019: Valneva: Renowned Vaccinologist Dr. Stanley Plotkin to Present on VLA-15 at R&D Investor Day in New York City
Jul 01, 2019: Valneva initiates second phase 2 study for its Lyme Disease Vaccine Candidate VLA15
Jun 12, 2019: Valneva reports successful outcome of phase 2 run-in for its lyme disease vaccine candidate
Jun 11, 2019: Valneva to present Lyme Disease vaccine update at R&D Investor Day in New York City on July 9th
Apr 09, 2019: Valneva to present on Lyme vaccine candidate at the 19th World Vaccine Congress
Jan 31, 2019: VALNEVA reports positive initial booster data and final phase 1 data for its lyme disease vaccine candidate
Dec 17, 2018: Valneva starts Phase ll trial of VLA15 to treat Lyme disease
Oct 25, 2018: VALNEVA receives positive feedback from EMA on its further development for lyme disease vaccine VLA15
Jul 02, 2018: Valneva Announces Significant Progress of its Lyme Disease Vaccine Candidate
Mar 29, 2018: VALNEVA to Present on Lyme disease candidate VLA-15 at the 18th World Vaccine Congress in Washington, D.C.
Mar 19, 2018: VALNEVA Reports Positive Phase I Interim Results for Its Lyme Vaccine Candidate VLA15
Jul 24, 2017: VALNEVA Receives FDA Fast Track Designation for its Lyme Disease Vaccine Candidate VLA15
Dec 09, 2016: Valneva Receives FDA and European Approvals to Start Clinical Testing of Lyme Disease Vaccine Candidate
Jul 12, 2016: European Investment Bank Grants Valneva a EU25 Million Loan to Fund R&D Activities
Mar 24, 2016: VALNEVA to present at the 16th World Vaccine Congress in Washington D.C.
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Number of Products under Development for Lyme Disease, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Lyme Disease - Pipeline by Inovio Pharmaceuticals Inc, H2 2019
Lyme Disease - Pipeline by NovoBiotic Pharmaceuticals LLC, H2 2019
Lyme Disease - Pipeline by Valneva SE, H2 2019
Lyme Disease - Dormant Projects, H2 2019
Number of Products under Development for Lyme Disease, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Lyme Disease - Overview
Lyme Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Lyme Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Lyme Disease - Companies Involved in Therapeutics Development
Inovio Pharmaceuticals Inc
NovoBiotic Pharmaceuticals LLC
Valneva SE
Lyme Disease - Drug Profiles
azithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Inhibit CRASP1 for Lyme Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
desloratadine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit OspA for Lyme Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lyme disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lyme disease vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Outer Surface Protein A for Lyme Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Lyme Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Lyme Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VLA-15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lyme Disease - Dormant Projects
Lyme Disease - Product Development Milestones
Featured News & Press Releases
Jul 03, 2019: Valneva: Renowned Vaccinologist Dr. Stanley Plotkin to Present on VLA-15 at R&D Investor Day in New York City
Jul 01, 2019: Valneva initiates second phase 2 study for its Lyme Disease Vaccine Candidate VLA15
Jun 12, 2019: Valneva reports successful outcome of phase 2 run-in for its lyme disease vaccine candidate
Jun 11, 2019: Valneva to present Lyme Disease vaccine update at R&D Investor Day in New York City on July 9th
Apr 09, 2019: Valneva to present on Lyme vaccine candidate at the 19th World Vaccine Congress
Jan 31, 2019: VALNEVA reports positive initial booster data and final phase 1 data for its lyme disease vaccine candidate
Dec 17, 2018: Valneva starts Phase ll trial of VLA15 to treat Lyme disease
Oct 25, 2018: VALNEVA receives positive feedback from EMA on its further development for lyme disease vaccine VLA15
Jul 02, 2018: Valneva Announces Significant Progress of its Lyme Disease Vaccine Candidate
Mar 29, 2018: VALNEVA to Present on Lyme disease candidate VLA-15 at the 18th World Vaccine Congress in Washington, D.C.
Mar 19, 2018: VALNEVA Reports Positive Phase I Interim Results for Its Lyme Vaccine Candidate VLA15
Jul 24, 2017: VALNEVA Receives FDA Fast Track Designation for its Lyme Disease Vaccine Candidate VLA15
Dec 09, 2016: Valneva Receives FDA and European Approvals to Start Clinical Testing of Lyme Disease Vaccine Candidate
Jul 12, 2016: European Investment Bank Grants Valneva a EU25 Million Loan to Fund R&D Activities
Mar 24, 2016: VALNEVA to present at the 16th World Vaccine Congress in Washington D.C.
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List Of Tables
Number of Products under Development for Lyme Disease, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Lyme Disease - Pipeline by Inovio Pharmaceuticals Inc, H2 2019
Lyme Disease - Pipeline by NovoBiotic Pharmaceuticals LLC, H2 2019
Lyme Disease - Pipeline by Valneva SE, H2 2019
Lyme Disease - Dormant Projects, H2 2019
List Of Figures
Number of Products under Development for Lyme Disease, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
RELATED REPORTS
Lyme Disease - Pipeline Insight, 2021
DelveInsights, Lyme Disease - Pipeline Insight, 2021, report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Lyme Disease pipeline landscape. It covers the pipeline drug profiles, including
View ReportNAD+ ADP Ribosyltransferase (Poly Adenosine Diphosphate Ribose Polymerase or PARP or EC 2.4.2.30) - Drugs in Development, 2021
NAD+ ADP Ribosyltransferase (Poly Adenosine Diphosphate Ribose Polymerase or PARP or EC 2.4.2.30) - Drugs in Development, 2021NAD+ ADP Ribosyltransferase (Poly Adenosine Diphosphate Ribose Polymerase or PARP or EC 2.4.2.30)
View ReportLyme Disease Diagnostics Market USA Europe Japan
This report presents test volumes and sale forecasts for the US, Europe (France, Germany, Italy, Spain, UK) and Japan. The report provides volume and sales forecasts for Lyme Disease tests
View ReportGlobal Lyme disease Market Outlook
The global marketplace for Lyme disease diagnostic is projected to grow due to the accelerating number of patients affected by Lyme diseases. Lyme disease is a communicable disease caused by
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
